You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
VX 809/770 Phase 2 interim results - 5-10% improvement in lung function
- Thread starter jamesB
- Start date
I agree bigstar. The only negative is the sweat chloride levels compared to the significant changes we saw with 770 and G511D. Is certainly good news that FEV1 levels were comparable though.
Will be interesting to see the sweat chloride results from the 2a 661 trial. They shouldn't be far away at all given how quickly these interim results were released.
Will be interesting to see the sweat chloride results from the 2a 661 trial. They shouldn't be far away at all given how quickly these interim results were released.
I agree bigstar. The only negative is the sweat chloride levels compared to the significant changes we saw with 770 and G511D. Is certainly good news that FEV1 levels were comparable though.
Will be interesting to see the sweat chloride results from the 2a 661 trial. They shouldn't be far away at all given how quickly these interim results were released.
Will be interesting to see the sweat chloride results from the 2a 661 trial. They shouldn't be far away at all given how quickly these interim results were released.
At the risk of getting too far ahead of myself, does anyone know how these drugs would affect other drug regimens, e.g., enzymes, physical therapy, nebs? Will people continue these treatments? What is the experience of people on Kalydeco? Have they been continuing treatments? Thanks!
At the risk of getting too far ahead of myself, does anyone know how these drugs would affect other drug regimens, e.g., enzymes, physical therapy, nebs? Will people continue these treatments? What is the experience of people on Kalydeco? Have they been continuing treatments? Thanks!
C
cfsucks
Guest
good news- i want to see the impact on people with only one df508 gene!
C
cfsucks
Guest
good news- i want to see the impact on people with only one df508 gene!
S
sdelorenzo
Guest
I need someone to explain this to me.
17/37 FEV1 was greater than 5%.
11/37 FEV1 was greater than 10%.
Does that mean 11 of the 17 were greater than 10%, so only 46% saw a change greater than 5%? So 54% did not see a significant change?
or does it mean a total of 85% saw a change greater than 5%?
Thank you,
Sharon
17/37 FEV1 was greater than 5%.
11/37 FEV1 was greater than 10%.
Does that mean 11 of the 17 were greater than 10%, so only 46% saw a change greater than 5%? So 54% did not see a significant change?
or does it mean a total of 85% saw a change greater than 5%?
Thank you,
Sharon
S
sdelorenzo
Guest
I need someone to explain this to me.
17/37 FEV1 was greater than 5%.
11/37 FEV1 was greater than 10%.
Does that mean 11 of the 17 were greater than 10%, so only 46% saw a change greater than 5%? So 54% did not see a significant change?
or does it mean a total of 85% saw a change greater than 5%?
Thank you,
Sharon
17/37 FEV1 was greater than 5%.
11/37 FEV1 was greater than 10%.
Does that mean 11 of the 17 were greater than 10%, so only 46% saw a change greater than 5%? So 54% did not see a significant change?
or does it mean a total of 85% saw a change greater than 5%?
Thank you,
Sharon
That's a good question. My interpretation was that those that saw the 10% increase were a part of the 17. So only 46% saw an improvement. The other 54% increased by less than 5%. I certainly could be wrong though - and hope I am. Analysts were pressing for an average FEV1 increase (mean) which Vertex said wouldn't be available until the final results were released.
That's a good question. My interpretation was that those that saw the 10% increase were a part of the 17. So only 46% saw an improvement. The other 54% increased by less than 5%. I certainly could be wrong though - and hope I am. Analysts were pressing for an average FEV1 increase (mean) which Vertex said wouldn't be available until the final results were released.